Please assess the completion status of the following clinical trial:

Trial Title: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Continue to meet all demographic and procedural~inclusion criteria of the A7501013 trial to enter into~this extension trial.~* Have demonstrated an acceptable degree of compliance~and completed the A7501013 trial, and would benefit~from continued treatment according to the investigator.~Exclusion Criteria:~* Have an uncontrolled, unstable clinically significant~medical condition.~* Have been judged to be medically noncompliant in the~management of their disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- asenapine (Type: EXPERIMENTAL): None
- olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).